Nuwellis (NASDAQ:NUWE – Get Free Report) and Bausch + Lomb (NYSE:BLCO – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.
Volatility and Risk
Nuwellis has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.
Institutional and Insider Ownership
3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 1.4% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuwellis | $8.27 million | 0.14 | -$17.52 million | ($132.59) | -0.00 |
| Bausch + Lomb | $5.10 billion | 1.22 | -$360.00 million | ($0.48) | -36.34 |
Nuwellis has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Nuwellis and Bausch + Lomb, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuwellis | 1 | 0 | 0 | 0 | 1.00 |
| Bausch + Lomb | 1 | 7 | 6 | 1 | 2.47 |
Bausch + Lomb has a consensus price target of $19.46, indicating a potential upside of 11.58%. Given Bausch + Lomb’s stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Nuwellis.
Profitability
This table compares Nuwellis and Bausch + Lomb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuwellis | -123.38% | -623.14% | -147.34% |
| Bausch + Lomb | -3.21% | 4.14% | 1.93% |
Summary
Bausch + Lomb beats Nuwellis on 12 of the 15 factors compared between the two stocks.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
